Waldencast stock tumbles on plan to delist from Nasdaq
Waldencast (WALD) shares dropped 15.3% premarket after announcing plans to delist from Nasdaq by October 2026, citing high costs and low trading volume. The company, now a single-brand entity post-Obagi Medical sale, may rename to Milk Makeup and trade OTC under 'MLKM'. SEC deregistration is expected to follow.
How this was made
The 30-second read
Why it matters
The voluntary delisting removes SEC reporting obligations, cuts $18.5 M in headquarters costs, and forces a move to OTC trading under a new ticker.
Market read
The announcement caused a 15% pre‑market drop, indicating immediate market reaction and potential spillover to similar small‑cap AI stocks.
What to watch
Potential cost savings from delisting could improve long‑term cash flow, offsetting short‑term price pressure.
Background
Waldencast plc, after divesting Obagi Medical, is transitioning to a single‑brand company and seeks to reduce public‑company costs.
Ticker impact
Shares fell 15.3% in pre‑market after the company announced a voluntary Nasdaq delisting and Form 25 filing.
Expect continued intraday decline of 5‑10% as investors unwind positions.
Primary corporate action, double‑digit move, and loss of Nasdaq listing reduce market access and visibility.
Market effects
AI‑related stocks may see broader pressure as Waldencast’s delisting highlights listing‑cost concerns for small AI firms.
US small‑cap market may experience slight liquidity strain from the removal of a Nasdaq component.
Limited to US markets; no direct global effect beyond sector sentiment.
Counterpoint
Some investors may view the delisting as a chance to buy at a discounted price if the company can thrive OTC.
Key entities
- companyWaldencast plc
AI‑focused firm announcing Nasdaq delisting.
- governing_bodyBoard of Directors
Approved the delisting and proposed renaming to Milk Makeup plc.
